




PHARMACEUTICAL 2023

GeoVax Labs Inc.
Rank 124 of 446





PHARMACEUTICAL 2023

GeoVax Labs Inc.
Rank 124 of 446



The relative strengths and weaknesses of GeoVax Labs Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GeoVax Labs Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of GeoVax Labs Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 176%, being 133% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	28,939
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,748
Liabilities, Non-Current	0
Other Assets	2,174
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	7.4
Other Revenues	82
Property and Equipment	235
Research and Development	9,123
Selling, General and Administrative Expense	4,987

Output Variable	Value in 1000 USD
Assets	31,348
Liabilities	4,748
Expenses	14,110
Revenues	82
Stockholders Equity	26,600
Net Income	-14,021
Comprehensive Net Income	-14,021
Economic Capital Ratio	176%